ranibizumab intravitreal injection
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy
Conditions
Polypoidal Choroidal Vasculopathy
Trial Timeline
Jan 1, 2007 → Sep 1, 2010
NCT ID
NCT00424710About ranibizumab intravitreal injection
ranibizumab intravitreal injection is a phase 1 stage product being developed by Pacific Biosciences for Polypoidal Choroidal Vasculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00424710. Target conditions include Polypoidal Choroidal Vasculopathy.
What happened to similar drugs?
5 of 7 similar drugs in Polypoidal Choroidal Vasculopathy were approved
Approved (5) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00424710 | Phase 1 | Completed |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 27 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 35 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 43 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 40 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 43 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 39 |
| Aflibercept Intravitreous Injection | Bayer | Approved | 47 |
| aflibercept 8 mg | Bayer | Phase 3 | 44 |
| aflibercept | Bayer | Approved | 40 |